Journal of Clinical Immunology

, Volume 31, Issue 4, pp 719–727 | Cite as

Increased T cell Immunoglobulin and Mucin Domain 3 Positively Correlate with Systemic IL-17 and TNF-α Level in the Acute Phase of Ischemic Stroke

  • Di Zhao
  • Nan Hou
  • Min Cui
  • Ying Liu
  • Xiaohong Liang
  • Xuewei Zhuang
  • Yuanyuan Zhang
  • Lining Zhang
  • Deling Yin
  • Lifen Gao
  • Yun Zhang
  • Chunhong Ma


Tim-3 has been linked to several inflammatory diseases by regulation on both adaptive and innate immunities. Here, we assessed the augmented expression of Tim-3 in brain tissue of ischemia–reperfusion mice and PBMCs of ischemic stroke (IS) patients. The augmented expression of Tim-3 significantly correlated with abnormal lipid levels. In vitro studies showed that plasma from ischemic stroke patients induced Tim-3 expression in THP-1 cells. More importantly, our results revealed a significant correlation of Tim-3 expression on CD4+ T cells with systemic IL-17 in patients with ischemic stroke. Consistently, we also found a positive correlation of Tim-3 expression on CD14+ monocytes and serum TNF-α in IS patients. Collectively, augmented expression of Tim-3 may play an important role in the pathogenesis of ischemic stroke by regulation of proinflammatory cytokines. Further studies will give us new insights on the pathogenesis of ischemic stroke and potentially provide a new target at the medical therapy.


Tim-3 ischemic stroke TNF-alpha IL-17 



This work was supported in part by grants from the National Nature Science Foundation of China (no. 30972753) and the National Basic Research Program (no. 2009CB521900), Independent Innovation Foundation of Shandong University (IIFSDU), and Shandong Provincial Nature Science Foundation for Distinguished Young Scholars JQ200907.


  1. 1.
    Hankey GJ. Stroke: how large a public health problem and how can the neurologist help? Arch Neurol. 1999;56(6):748–54.PubMedCrossRefGoogle Scholar
  2. 2.
    Mitchell SV, Elkind, Tai W, Kristen C, Paik MC, Sacco RL. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med. 2006;166:2073–80.CrossRefGoogle Scholar
  3. 3.
    Nobuya I, Olga P, Reuhl KR, Oleg M. Inflammatory response and glutathione peroxidase in a model of stroke. J Immunol. 2002;168:1926–33.Google Scholar
  4. 4.
    Foulkes MA, Wolf PA, Price TR, Mohr JP, Hier DB. The Stroke Data Bank: design, methods, and baseline characteristics. Stroke. 1988;19:547–54.PubMedCrossRefGoogle Scholar
  5. 5.
    Offner H, Subramanian S, Parker SM, Afentoulis ME, Vandenbark AA, Hurn PD. Experimental stroke induces massive, rapid activation of the peripheral immune system. J Cereb Blood Flow Metab. 2006;26:654–65.PubMedCrossRefGoogle Scholar
  6. 6.
    Vogelgesang A, Grunwald U, Langner S, Jack R, Bröker BM, Kessler C, et al. Analysis of lymphocyte subsets in patients with stroke and their influence on infection after stroke. Stroke. 2008;39:237–41.PubMedCrossRefGoogle Scholar
  7. 7.
    Ross AM, Hurn P, Perrin N, Wood L, Carlini W, Potempa K. Evidence of the peripheral inflammatory response in patients with transient ischemic attack. J Stroke Cerebrovasc Dis. 2007;16:203–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Yang QW, Li JC, Lu FL, Wen AQ, Xiang J, Zhang LL, et al. Upregulated expression of toll-like receptor 4 in monocytes correlates with severity of acute cerebral infarction. J Cereb Blood Flow Metab. 2008;28:1588–96.PubMedCrossRefGoogle Scholar
  9. 9.
    Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002;415:536–41.PubMedCrossRefGoogle Scholar
  10. 10.
    Kuchroo VK, Umetsu DT, DeKruyff RH, Freeman GJ. The TIM gene family: emerging roles in immunity and disease. Nat Rev Immunol. 2003;3:454–62.PubMedCrossRefGoogle Scholar
  11. 11.
    Khademi M, Illés Z, Gielen AW, Marta M, Takazawa N, Baecher-Allan C, et al. T cell Ig- and mucindomain- containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis. J Immunol. 2004;172:7169–76.PubMedGoogle Scholar
  12. 12.
    Anderson AC, Anderson ED, Bregoli L, Hastings WD, Kassam N, Charles L, et al. Promotion of tissue inflammation by the immune receptor TIM-3 expressed on innate immune cells. Science. 2007;318:1141–3.PubMedCrossRefGoogle Scholar
  13. 13.
    Sánchez-Fueyo A, Tian J, Picarella D, Domenig C, Zheng XX, Sabatos CA, et al. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol. 2003;4:1093–101.PubMedCrossRefGoogle Scholar
  14. 14.
    Zhao J, Zhang L, Liu Y, Li B, Zhang L, Fang H, et al. Human pregnancy up-regulates Tim-3 in innate immune cells for systemic immunity. J Immunol. 2009;182:6618–24.PubMedCrossRefGoogle Scholar
  15. 15.
    Yang G, Kitagawa K, Matsushita K, Mabuchi T, Yagita Y, Yanagihara T, et al. C57BL/6 strain is most susceptible to cerebral ischemia following bilateral common carotid occlusion among seven mouse strains: selective neuronal death in the murine transient forebrain ischemia. Brain Res. 1997;752:209–18.PubMedCrossRefGoogle Scholar
  16. 16.
    Fujii M, Hara H, Meng W, Vonsattel J, Huang Z, Moskowitz MA. Strain-related differences in susceptibility to transient forebrain ischemia in SV-129 and C57black/6 mice. Stroke. 1997;28:1805–11.PubMedCrossRefGoogle Scholar
  17. 17.
    Wang Y, Meng J, Wang X, Liu S, Shu Q, Gao L, et al. Expression of human TIM-1 and TIM-3 on lymphocytes from systemic lupus erythematosus patients. Scand J Immunol. 2008;67:63–70.PubMedCrossRefGoogle Scholar
  18. 18.
    Vogelgesang A, May VE, Grunwald U, Bakkeboe M, Langner S, Wallaschofski H, et al. Functional status of peripheral blood T-cells in ischemic stroke patients. PLoS ONE. 2010;5:e8718.PubMedCrossRefGoogle Scholar
  19. 19.
    Vila N, Castillo J, Dávalos A, Chamorro A. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke. 2000;31:2325–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Vila N, Castillo J, Dávalos A, Esteve A, Planas AM, Chamorro A. Levels of anti-inflammatory cytokines and neurological worsening in acute ischemic stroke. Stroke. 2003;34:671–5.PubMedCrossRefGoogle Scholar
  21. 21.
    Castellanos M, Castillo J, García MM, Leira R, Serena J, Chamorro A, et al. Inflammation-mediated damage in progressing lacunar infarctions: a potential therapeutic target. Stroke. 2002;33:982–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Chamorro A, Planas AM. Inflammation-mediated damage as a potential therapeutic target in acute ischemic stroke. Ernst Schering Res Found Worksho. 2004;47:185–204.Google Scholar
  23. 23.
    Frisancho-Kiss S, Nyland JF, Davis SE, Masheka V, Barrett, Gatewood SJL, et al. T cell Ig mucin-3 reduces inflammatory heart disease by increasing CTLA-4 during innate immunity. J Immunol. 2006;176:6411–5.PubMedGoogle Scholar
  24. 24.
    Tziomalos K, Athyros VG, Karaqiannis A, Mikhailidis DP. Dyslipidemia as a risk factor for ischemic stroke. Curr Top Med Chem. 2009;9:1291–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Sierra-Johnson J, Somers VH, Kuniyoshi FH, Garza CA, Isley WL, Gami AS, et al. Comparison of apolipoprotein-B/apolipoprotein-A1 in subjects with versus without the metabolic syndrome. Am J Cardiol. 2006;98:1369–73.PubMedCrossRefGoogle Scholar
  26. 26.
    Hallenbeck JM. The many faces of tumor necrosis factor in stroke. Nat Med. 2002;8:1363–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Sotgiu S, Zanda B, Marchetti B, Fois ML, Arru G, Pes GM, et al. Inflammatory biomarkers in blood of patients with acute brain ischemia. Eur J Neurol. 2006;13:505–13.PubMedCrossRefGoogle Scholar
  28. 28.
    Barone FC, Arvin B, White RF, Miller A, Webb CL, Willette RN, et al. Tumor necrosis factor-alpha. A mediator of focal ischemic brain injury. Stroke. 1997;28:1233–44.PubMedCrossRefGoogle Scholar
  29. 29.
    Kostulas N, Pelidou SH, Kivisäkk P, Kostulas PV, Link H. Increased IL-1ß, IL-8, and IL-17 mRNA expression in blood mononuclear cells observed in a prospective ischemic stroke study. Stroke. 1999;30:2174–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Shichita T, Sugiyama Y, Ooboshi H, Sugimori H, Nakagawa R, Takada I, et al. Pivotal role of cerebral interleukin-17-producing gammadelta T cells in the delayed phase of ischemic brain injury. Nat Med. 2009;15:946–50.PubMedCrossRefGoogle Scholar
  31. 31.
    Nakae S, Iwakura Y, Suto H, Galli SJ. Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17. J Leukoc Biol. 2007;81:1258–68.PubMedCrossRefGoogle Scholar
  32. 32.
    Li G-Z, Zhong D, Yang L-M, Sun B, Zhong Z-H, Yin Y-H, et al. Expression of interleukin-17 in ischemic brain tissue. Scand J Immuno. 2005;62:481–6.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Di Zhao
    • 1
  • Nan Hou
    • 1
  • Min Cui
    • 3
  • Ying Liu
    • 1
  • Xiaohong Liang
    • 1
  • Xuewei Zhuang
    • 4
  • Yuanyuan Zhang
    • 5
  • Lining Zhang
    • 1
  • Deling Yin
    • 6
  • Lifen Gao
    • 1
  • Yun Zhang
    • 2
  • Chunhong Ma
    • 1
  1. 1.Key Laboratory for Experimental Teratology of the Ministry of Education and Institute of ImmunologyShandong University School of MedicineJinanPeople’s Republic of China
  2. 2.The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of HealthShandong University Qilu HospitalJinanPeople’s Republic of China
  3. 3.Department of PhysiologyShandong University School of MedicineJinanPeople’s Republic of China
  4. 4.Shandong University Qilu HospitalJinanPeople’s Republic of China
  5. 5.Jinan Central Hospital affiliated to Shandong UniversityJinanPeople’s Republic of China
  6. 6.Department of Pharmacology, College of MedicineEast Tennessee State UniversityJohnson CityUSA

Personalised recommendations